Congratulations to winners of the 2023 Ross Prize in Molecular Medicine: Jonathan Cohen, PhD and Helen Hobbs, MD.
Nominations for the 2024 Ross Prize in Molecular Medicine are now open. Submit your nominations by 15 November 2023. Find out more.
Ross Prize in Molecular Medicine
Dr. Betty Diamond elected to National Academy of Sciences
Please join us in congratulating Dr. Betty Diamond, Editor in Chief of Feinstein’s flagship journal Molecular Medicine, on her election to the National Academy of Sciences.
Please find further details regarding the announcement here.
Call for Papers: Targeting the host-microbiome interface in chronic inflammatory diseases
Edited by
Gerard Honig, Celsius Therapeutics, USA
Call for Papers: Preparing for the next pandemic: a molecular medicine approach
Edited by
Douglas Nixon, Weill Cornell Medical College, USA
Johan Sandberg , Karolinska Institute, Sweden
Aims and scope
Molecular Medicine is an open access journal publishing recent findings that elucidate disease pathogenesis at the molecular or physiological level, which may lead to the design of specific tools for disease diagnosis, treatment, or prevention. Manuscripts containing material relevant to the genetic, molecular, or cellular basis of key physiologic or disease processes are considered for publication. Manuscripts submitted to Molecular Medicine should describe the implications of the results for human disease and medicine, at a level approachable by our broad audience.
Criteria to consider for studies involving lnc-RNAs or micro-RNAs:
· As lncRNAs and miRNAs have multiple targets, claims of their function mediated by a single target or pathway will not be accepted, unless multiple additional targets are investigated to support functional specificity.
· The rationale to investigate a specific lncRNA or miRNA needs to be specified upfront in the introduction and justified in the context of other miRNAs known to be functional in that specific field.
· The proposed function of the lnc-RNA or miRNA should be validated by gain and loss of function studies.
· Primary cells should be used whenever possible to confirm findings in cell lines.
· In depth investigation in the signaling pathway(s) regulated by the RNA species should be conducted.
· Insight into the regulation of the RNA species and how it relates to the pathologic state should be provided.
· If applicable: Details of initial screen used to identify RNA species involvement in pathway/disease (number of subjects, statistical tests employed, percent change from controls).
Nobel congratulations to William G. Kaelin Jr
Molecular Medicine is happy to congratulate William G. Kaelin Jr on being a winner of The Nobel Prize in Physiology or Medicine 2019. Professor Kaelin Jr was chosen for his work on the discoveries of how cells sense and adapt to oxygen availability. He previously contributed an article to our journal, "The Molecular Basis of Von Hippel-Lindau Disease", which you can read here.
Reviewers of the Quarter
Molecular Medicine would like to recognize the efforts of the following peer reviewers, for their excellent service during the fourth quarter of 2022. These individuals have all exceeded expectations as far as acceptance rate, the number of completed reviews, and timeliness. The journal cannot succeed without its peer reviewers, and we thank these hard-working members of our network:
Fourth Quarter of 2022: Dr. Mohan Babu
Articles
-
-
The pre-conception maternal exposure to Sofosbuvir affects the mitochondrial biogenesis in prenatal fetal tissues: Experimental study on rats
-
Rad1 attenuates DNA double-strand breaks and cell cycle arrest in type II alveolar epithelial cells of rats with bronchopulmonary dysplasia
-
Plasma-derived small extracellular vesicles unleash the angiogenic potential in head and neck cancer patients
-
Cancer-associated fibroblasts and its derived exosomes: a new perspective for reshaping the tumor microenvironment
-
Erythropoiesis: insights into pathophysiology and treatments in 2017
-
Post-sepsis syndrome – an evolving entity that afflicts survivors of sepsis
-
Serum amyloid A – a review
-
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
-
Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism
Top 10: Most Cited Articles of 2019 and 2020
Neuroinflammation: friend and foe for ischemic stroke
Richard L. Jayaraj, Sheikh Azimullah, Rami Beiram, Fakhreya Y. Jalal, & Gary A. Rosenberg
Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis
Qianquan Ma, Changsheng Xing, Wenyong Long, Helen Y. Wang, Qing Liu, & Rong-Fu Wang
Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease
Lin, CH., Chen, CC., Chiang, HL. et al
The endotoxin hypothesis of neurodegeneration
Guy C. Brown
Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles
Sylwia Dabrowska, Anna Andrzejewska, Barbara Lukomska, & Miroslaw Janowski
Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization
Liu, W., Rong, Y., Wang, J. et al.
The progress of gut microbiome research related to brain disorders
Sibo Zhu, Yanfeng Jiang, Kelin Xu, Mei Cui, Weimin Ye, Genming Zhao, Li Jin, & Xingdong Chen
Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway
Zusso, M., Lunardi, V., Franceschini, D. et al.
Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports
Najjar, S., Najjar, A., Chong, D.J. et al.
Glial activation and inflammation along the Alzheimer’s disease continuum
Nordengen, K., Kirsebom, BE., Henjum, K. et al.
Featured cross-journal series: Molecular mechanisms and therapeutic relevance of neuro-immune communication
Our new cross-journal thematic series (published in conjunction with Bioelectronic Medicine), calls for submissions focusing on the molecular mechanisms and therapeutic exploration at the interface between the immune and nervous systems in health and disease and the therapeutic exploration of this insight. It will also cover emerging areas such as the neuronal regulation of hematopoiesis and innate and adaptive immunity. The series is guest edited by Sangeeta Chavan, Colin Reardon, and Niccolò Terrando. Find more information here.
Awards
Anthony Cerami Award in Translational Medicine
Molecular Medicine has established the Anthony Cerami Award in Translational Medicine to honor investigators who have created the fundamental innovation necessary for molecular medicine to advance into clinical practice. The award recognizes leading edge discoveries that have led to improvement of human health, and have opened the door to new therapeutic advances and understanding. Find out more.
Ross Prize in Molecular Medicine
The annual Ross Prize in Molecular Medicine is established in conjunction with the Feinstein Institutes for Medical Research and Molecular Medicine. The winner will be an active investigator having produced innovative, paradigm-shifting research that is worthy of significant and broad attention in the field of molecular medicine. Find out more. Please see more information about the 2023 Ross Prize Symposium on Genetic Basis of Lipid Metabolism Disorders here.
Announcing our new article types
Our journal is proud to offer four new article types, ready for submissions!
- Mini-reviews, which provide a concise summary of a specific research topic or field relevant to our scope
- Perspectives, which grants the opportunity to write about the current state and recent developments of a research field or topic within our scope and point to associated challenges and future directions
- Opinions, written with a specific focus on a previously published article which has had a major impact on the field.
- Commentaries, invited pieces which provide further discussion on a primary research manuscript.
Please see our Submission Guidelines page for more.
Reviewers of the quarter
Molecular Medicine would like to recognize the efforts of the exceptional peer reviewers, for their excellent service. This individual has exceeded expectations as far as acceptance rate, the number of completed reviews, and timeliness, during the first and second quarter of 2022. The journal cannot succeed without its peer reviewers, and we thank the hard-working members of our network.
Dr. Paula Felippe Martinez - Second Quarter of 2022
Dr. Christos K. Kontos - First Quarter of 2022
About the Editors
Dr Betty Diamond (Editor-in-Chief) graduated with a BA from Harvard University and an MD from Harvard Medical School. She performed a residency in Internal Medicine at Columbia Presbyterian Medical Center and received postdoctoral training in immunology at the Albert Einstein College of Medicine.
Dr Diamond has headed the Rheumatology Divisions at Albert Einstein School of Medicine and at Columbia University Medical Center. She also directed the Medical Scientist Training Program at Albert Einstein School of Medicine for many years. She is currently head of the Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases at The Feinstein Institutes for Medical Research and Director of the PhD and MD/PhD programs at the Zucker School of Medicine at Hofstra-Northwell.
A past president of the American Association of Immunology, Dr Diamond has also served on the Board of Directors of the American College of Rheumatology and the Scientific Council of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Dr Diamond is a Fellow of the American Association for the Advancement of Science (AAAS) and a member of the National Academy of Medicine.
Valentin Pavlov, The Feinstein Institutes for Medical Research, USA- Executive Editor
Maria Ruggieri, The Feinstein Institutes for Medical Research, USA- Managing Editor
Sonya VanPatten, The Feinstein Institutes for Medical Research, USA- Coordinating Editor
Message from the Editors
What happens when the immune system goes rogue?
In her 2017 TEDMED Talk, Editor-in-Chief Dr Betty Diamond discusses the latest insights in autoimmune disease research, and the pivotal role that patients play in studies.
Pre-submission inquiries
The Editors of Molecular Medicine welcome authors to send any pre-submission inquiries they might have, here. We ask that you please include “Pre-submission inquiry” in the subject line of your email and that you include the title and abstract of your proposed submission within the message. Our Editors will do their best to respond to you in a timely manner.
Bioelectronic Medicine
If you enjoy Molecular Medicine, we invite you to visit Feinstein’s Bioelectronic Medicine (published by BMC). Bioelectronic Medicine focuses on the regulatory functions of the nervous system and technologies that record, stimulate, or block neural signaling to affect specific molecular mechanisms in health and disease. It also features bioelectronic approaches for monitoring and controlling biological processes and for providing insights into disease pathogenesis that can be utilized in new treatments of inflammatory, neurodegenerative, gastrointestinal, and cardiovascular diseases, paralysis, and many other conditions.
About Feinstein Institutes for Medical Research
Molecular Medicine is published in partnership with The Feinstein Institutes for Medical Research. As the research arm of Northwell Health, the largest healthcare provider in New York, it is home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities. The Feinstein Institutes include 4,000 researchers and staff who are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how the Feinstein Institutes empower imagination and pioneers discovery, visit FeinsteinInstitute.org.
Annual Journal Metrics
-
Citation Impact
6.382 - 2-year Impact Factor (2021)
6.150 - 5-year Impact Factor (2021)Speed
7 days to first decision for all manuscripts (Median)
24 days to first decision for reviewed manuscripts only (Median)Usage
942,150 downloads (2022)
742 Altmetric mentions (2021)